compounded versions ran $200 to $400/mo Litigation including 5th Circuit cases on FDA shortage authority is unresolved Foundational precedent for future high-cost branded drug access debates 503B framework was created in 2013 after the NECC meningitis disaster, which killed dozens Table of Contents Video Preview Podcast, Part I (Free) Abstract The April 30 Proposal in Plain Language How 503A and 503B Actually Work, and Why the Bulks List Matters The Shortage Window That Built the Parallel Market Clinical Need vs Economic Need, and Why That Split Travels Beyond Obesity The Quiet Pharmaceutical Layer the Compounding Boom Built What Happens to Telehealth, Cash Pay Clinics, and the Consumer Funnel Paywall Podcast Part II, Paid The 503A Pathway That Survives, and Why It Cannot Carry the Load Safety as Both Sword and Shield in the Recentralization Push Forward View on Personalized Compounding, Litigation, and the Next Therapeutic Category The April 30 Proposal in Plain Language The Federal Register notice that dropped on April 30, 2026 looks technical at first glance

Beebo off the Hook
The cellular content of astaxanthin accounts for up to 5% of the biomass dry weight of H
The primary fallacy lies in viewing the GLP-1 market as a zero-sum game
After surgery, the body needs to heal damaged tissues, whether they are muscles, tendons, or ligaments
GHK-Cu wins on tolerability